---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-119095"
form_type: "8-K"
ticker: "GPCR"
cik: "0001888886"
company_name: "Structure Therapeutics Inc."
filed_at: "2025-12-08T23:59:59+00:00"
generated_at: "2026-05-16T14:05:45.028369+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Structure Therapeutics reports positive Phase 2 data for oral GLP-1 aleniglipron; plans Phase 3 by mid-2026

## Summary
- Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) at 120 mg in Phase 2b ACCESS study; up to 15.3% (35.5 lbs) at 240 mg in exploratory ACCESS II.
- No AE-related discontinuations when starting at 2.5 mg in OLE and body composition studies, improving tolerability vs 5 mg start.
- No cases of drug-induced liver injury, persistent liver enzyme elevations, or QTc prolongation across all aleniglipron studies.
- Plans to request Type B End-of-Phase 2 meeting with FDA in H1 2026; Phase 3 program initiation expected by mid-2026.

## SEC filing metadata
- accession: 0001104659-25-119095
- form_type: 8-K
- ticker: GPCR
- cik: 0001888886
- company_name: Structure Therapeutics Inc.
- filed_at: 2025-12-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1888886/000110465925119095/0001104659-25-119095-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1888886/000110465925119095/tm2532078d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-119095
- JSON: https://secwatch.observer/filing/0001104659-25-119095.json
- Plain text: https://secwatch.observer/filing/0001104659-25-119095.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.